Innovation in Anti-VEGF Therapy for Retinal Diseases: Molecular Insights and Clinical Applications
home / case-based-roundtable-series / innovation-in-anti-vegf-therapy-for-retinal-diseases-molecular-insights-and-clinical
Michael W. Stewart, MD, discusses how high-dose aflibercept (8 mg) can achieve better anatomical and visual outcomes compared with standard anti-VEGF therapies in patients with treatment-resistant diabetic macular edema and neovascular age-related macular degeneration, demonstrating improved retinal drying and extended treatment durability through 3 detailed clinical cases.
New content coming soon.
